• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • The authors set out to answer a key question: What are the risks for breast cancer, ovarian cancer and contralateral breast cancer for those who carry pathogenic variants in BRCA1 and BRCA2 genes?
  • What is different about this study?
    • Prospective not retrospective
    • Study large enough to provide more precise risk / penetrance estimates
    • Study includes an analysis of risk associated with number of 1st and 2nd degree relatives and location of the variants within the gene

METHODS:

  • Large prospective cohort study
  • BRCA1 and BRCA2 carriers recruited via 3 consortia and were followed over several years

RESULTS:

Breast Cancer risks, based on 3886 women (median age 38)

  • BRCA1:
    • Peak breast cancer incidence increased rapidly until ages 30 to 40 then plateaus
    • Cumulative risk by age 80: 72% (95% CI, 65%-79%)
  • BRCA2:
    • Peak breast cancer incidence increased rapidly until 40 to 50 then plateaus
    • Cumulative risk by age 80: 69% (95% CI, 61%-77%)

Ovarian Cancer risks, based on 5066 women (median age 38)

  • BRCA1:
    • Cumulative risk by age 80: 44% (95% CI, 36%-53%)
  • BRCA2:
    • Cumulative risk by age 80: 17% (95% CI, 11%-25%)

Contralateral Breast Cancer risks at 20 years of follow up after 1st diagnosis, based on 2213 women (median age 47)

  • BRCA1:
    • Cumulative risk: 40% (95% CI, 35%-45%)
  • BRCA2:
    • Cumulative risk: 26% (95% CI, 20%-33%)

Family History risks

  • BRCA1:
    • Hazard ratio for ≥ 2 vs 0 affected relatives, 1.99 (95%CI, 1.41-2.82; P<.001)
  • BRCA2:
    • Hazard ratio for ≥ 2 vs 0 affected relatives, 1.91 (95%CI, 1.08-3.37; P=.02)

Mutation Position risks

  • BRCA1:
    • Higher if outside region bounded by positions c.2282-c.4071 (hazard ratio 1.46; 95%CI, 1.11-1.93; P=.007)
  • BRCA2:
    • Higher if outside region bounded by positions c.2831-c.6401 (hazard ratio, 1.93; 95%CI, 1.36-2.74; P<.001)

KEY POINTS:

  • Like previous studies, risk higher if first breast cancer diagnosed before age 40 vs after age 50 (P = .03)
  • Cumulative risks for ovarian cancer were low up until age 40 for BRCA1 and age 50 for BRCA2
  • Contralateral breast cancer risk lower in BRCA2 and may be due to increased estrogen receptor positive tumors, which are more receptive to hormonal therapies
  • Mutations in exon 11 of either gene had lower breast cancer risk but may have higher ovarian cancer risk

CONCLUSION:

  • The data in this study can be used to provide individualized counseling to BRCA1 and BRCA2 mutation carriers.

Learn More – Primary Sources:

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Obstetrics Critical Care Course
How has the use of the BRCA Test Changed from 2004-2014?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site